Finding new ways to treat lymphoma linked to Kaposi's sarcoma herpesvirus
Targeting IKKepsilon-mediated nucleotide synthesis in KSHV-associated lymphoma
This research looks for new ways to stop the growth of lymphoma cells caused by the Kaposi's sarcoma herpesvirus (KSHV), especially in people with weakened immune systems like those with AIDS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11138703 on NIH RePORTER |
What this research studies
We are exploring how the Kaposi's sarcoma herpesvirus (KSHV) uses a specific protein called IKKepsilon to help lymphoma cells grow and multiply. Our goal is to understand this process better and then use that knowledge to develop new treatments. We have created new drug-like molecules that can block IKKepsilon and other related enzymes, which could potentially stop the growth of these cancer cells. This work aims to find effective therapies for lymphomas that currently have limited treatment options.
Who could benefit from this research
Good fit: This foundational research is relevant to patients with KSHV-associated lymphomas, such as primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD), especially those who are immunocompromised.
Not a fit: Patients with lymphomas not associated with KSHV or other conditions would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new and more effective drug treatments for KSHV-associated lymphomas, offering hope to patients who currently have limited options.
How similar studies have performed: While antiviral therapy has limited efficacy, this approach of targeting IKKepsilon and metabolic enzymes is a novel strategy for KSHV-associated malignancies.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Feng, Pinghui — University of Southern California
- Study coordinator: Feng, Pinghui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.